Sarah Voytek

• Develop and oversee nonclinical & translational strategy of an autologous TCR Treg cell product for progressive multiple sclerosis • Establish relationships with academic scientists, contract research organizations and consultants to support pipeline programs

• Led Preclinical & Translational Development department in Severe Genetic Disease business unit supervising staff of Strategy Leads, Pharmacologists, Research Associates and a CRO Program Manager • Formalized translational science framework supporting late-stage clinical development and led Lenti- D and Zynteglo translational science teams • Monitored integrated pharmacology, efficacy and safety data across clinical programs • Investigated clinical safety events leading to regulatory submissions and scientific publications

• Led Preclinical & Translational Development Program Strategy team overseeing nonclinical development for bluebird bio pipeline programs – early research through Phase III clinical development • Engaged in INTERACT and pre-IND meetings with FDA on the development of gene-edited CAR T and HSC gene therapy products • Presented research data and nonclinical strategy considerations at scientific meetings and industry consortia

• Preclinical safety lead for programs in Cardiovascular & Metabolism, Infectious Disease, Neuroscience and Oncology disease areas • Designed and executed submission-enabling nonclinical development studies • Supported strategic portfolio acquisition and disposition of preclinical/clinical assets via due diligence opportunities • Drove the adoption of advanced microscopy techniques for in vitro and in vivo investigative safety applications

• Managed an investigative toxicology research laboratory to contextualize safety findings, support regulatory submissions and address health authority requests • Designed and directed preclinical studies in collaboration with internal and CRO teams

• Studied mechanisms of drug pharmacology and toxicology via molecular, cellular and biochemical approaches

• Established quantitative assays to expedite next-generation sequencing device development in collaboration with chemists, engineers and software developers

• Designed and synthesized randomized oligonucleotide libraries • Discovered novel catalytic RNAs capable of isothermal selective amplification • Expressed, purified, and characterized various recombinant bacterial proteins

• Prepared and characterized innovative macromolecular compounds to produce silica surfactants using multi-step organic synthesis